Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Free Cash Flow (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Free Cash Flow data on record, last reported at -$12.9 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 29.67% year-over-year to -$12.9 million; the TTM value through Dec 2025 reached -$55.3 million, down 68.11%, while the annual FY2025 figure was -$55.3 million, 68.11% down from the prior year.
  • Free Cash Flow reached -$12.9 million in Q4 2025 per CTNM's latest filing, down from -$12.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $40.6 million in Q2 2023 and bottomed at -$15.7 million in Q2 2025.
  • Average Free Cash Flow over 3 years is -$5.8 million, with a median of -$9.3 million recorded in 2024.
  • The widest YoY moves for Free Cash Flow: up 10.0% in 2024, down 121.2% in 2024.
  • A 3-year view of Free Cash Flow shows it stood at -$11.0 million in 2023, then rose by 10.0% to -$9.9 million in 2024, then fell by 29.67% to -$12.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$12.9 million in Q4 2025, -$12.3 million in Q3 2025, and -$15.7 million in Q2 2025.